Endonovo Therapeutics, Inc. (ENDV): Total Liabilities
Not updated since 2022-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
$33.46M
As of 2022-12-31
+12.1%
3-year compound annual growth
+18.8%
5-year compound annual growth
+32.8%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2022-12-31 | $33.46M | +88.2% | 2023-04-17, Balance as of period end |
| 2021-12-31 | $17.78M | +4.7% | 2023-04-17, Balance as of period end |
| 2020-12-31 | $16.98M | -28.6% | 2022-04-14, Balance as of period end |
| 2019-12-31 | $23.78M | +52.1% | 2021-04-13, Balance as of period end |
| 2018-12-31 | $15.63M | +10.4% | 2020-05-04, Balance as of period end |
| 2017-12-31 | $14.16M | +59.5% | 2019-04-15, Balance as of period end |
| 2016-12-31 | $8.88M | -8.3% | 2018-04-06, Balance as of period end |
| 2015-12-31 | $9.69M | +104.4% | 2017-04-17, Balance as of period end |
| 2014-12-31 | $4.74M | +12.7% | 2016-05-17, Balance as of period end |
| 2013-12-31 | $4.21M | +114.7% | 2015-06-15, Balance as of period end |
| 2012-12-31 | $1.96M | +36.0% | 2013-05-03, Balance as of period end |
| 2011-12-31 | $1.44M | n/a | 2013-05-03, Balance as of period end |